Answers are grounded in this paper and cite their sources.
Alcohol-induced liver disease (ALD) is a prevalent and serious health concern worldwide. The inflammatory response is a key factor in the development of ALD, making it an attractive target for therapeutic intervention. This study aimed to investigate the protective effects of Styela clava methanolic extract (SCM) against ALD and elucidate the underlying molecular mechanisms. In an in vitro model, human hepatocytes (HepG2 cells) were exposed to ethanol to induce liver injury, followed by treatment with SCM. The results demonstrated that SCM significantly improved cell viability, attenuated oxidative stress, reduced apoptosis, and decreased the production of inflammatory cytokines in HepG2 cells. Furthermore, SCM inhibited the activation of nuclear factor-kappa B (NF-κB) and MAPK pathways in vitro. The anti-inflammatory potential of SCM was further investigated using a zebrafish larval model. In this model, SCM mitigated alcohol-induced inflammation, as evidenced by improved cell survival, reduced nitric oxide (NO) production, and suppressed reactive oxygen species (ROS) production. These findings demonstrate the protective effects of SCM against ALD by inhibiting NF-κB and MAPK inflammatory pathways. Gas chromatography-mass spectrometry analysis indicated that SCM contained a higher concentration of 9-octadecenamide. Thus, SCM may hold promise as a natural therapeutic agent for the prevention and treatment of ALD, offering potential avenues for the development of novel interventions.
No takes yet. Share an insight, caveat, or question.
Liyanage et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: